The 51st Annual Meeting of the Japanese Society of Myeloma

General Presentation

1. Basic research on etiology, pathogenesis, and treatment
2. Immune microenvironment
3. Diagnostic methods (e.g., prognostic factors, biomarkers, MRD measurement, Genome testing)
4. First line treatment of myeloma
5. Treatment of relapsed/refractory myeloma
6. Novel therapies of myeloma (e.g., CAR-T therapy)
7. Response/risk-adapted therapy
8. Myeloma-related disorders
9. Prevention and management of infectious diseases
10. Evaluation and management of myeloma-associated bone diseases
11. Management of elderly myeloma patients
12. Cancer rehabilitation
13. Regional medical cooperation for elderly myeloma patient care (e.g., home nursing, home medical care, out)
14. Complications/Supportive care
15. Others
16. Encore Topic

Encore Topic

Submission Period:

• November 11 (Tue.), 2025 at noon - 
• December 23 (Tue.), 2025 at noon

• Please refer to▼the application guideline of Encore.

  Encore Presentation

  • 1) An abstract which, at the time of submission, is identical to or nearly unchanged from (an adaptation of) an abstract presented previously at a major overseas conference or similar event within one year prior to this Annual Meeting, but which has not been presented yet at past JSM Annual Meetings or other conferences or similar events in Japan, may be submitted in this category.
  • 2) There is a limit to the number of submissions accepted in this category.
  • 3) Submission requirements are as follows:
    
    • i. Abstracts in this category must have potential to gain new, highly meaningful scientific value through submission to and fresh discussion at the JSM Annual Meeting.
    • ii. The phrase “(Encore)” must be added to the end of the abstract’s title.
    • iii. If any copyright or similar exists for any part of the submission, the submitter is responsible for obtaining consent for submission and usage.
    • iv. In the case of copyrighted material usage, if said copyright holder is a scientific association, publishing company or similar, the final portion of the abstract must include a statement indicating that permission for copyrighted content submission and usage has been obtained as well as information on the original copyrighted material (original abstract or similar).
    • v. The primary author and any other co-author who will participate in the meeting must pay their registration fees for the JSM Annual Meeting. No fee payments will be refunded, regardless of selection results.
    • vi. No objection in response to review results will be recognized, regardless of selection results and any other factor.
    • vii. In all other respects, submissions must be made in accordance with rules for general presentation submissions.

For participants from overseas

Participants from overseas can submit without membership status, but are required to pay the registration fee. This registration fee is NOT REFUNDABLE despite the result of acceptance/rejection of the submission. This non-refundable condition is the same for the submission by the Japanese members.
Registration is scheduled to open in February 2026

Submission Requirements

The primary author (presenter) must be a member of the Japanese Society of Myeloma. Exceptions are permitted for early-career residents in the new training system, non-M.D. graduate students, undergraduate students, international students, and non-Japanese nationals, who may present their abstracts as the primary author regardless of membership.

Presentation Format

Oral presentation only

JSM Travel Award for IMS/IMW

JSM Travel Award for IMS/IMW is applicable for only the Japanese JSM members. Conditions of this award appears in the Japanese page. Application forms (Application Form, Recommendation Letter, English Abstract, Research Achievements) also appears in the Japanese page.

Abstract Submission and Book of Abstracts

The abstract book will be published by the International Journal of Myeloma to preserve the contents in a format readily available for future citations.

Conflict of Interest Disclosure

All authors are required to disclose any Conflict of Interest (COI) with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript within the period of 36 months prior. The primary author is required to complete the form below with information from all the authors listed in the manuscript.

Consideration of research ethics, etc.

When making a presentation at the annual meeting of the Japanese Society of Myeloma, the contents of the presentation must comply with the ethical guidelines, laws and regulations in each country. When submitting an abstract, please state one of the following two options based on the status; "This presentation has been approved by an ethics committee or institution for clinical or basic research" or "This presentation does not require approval by an ethics committee or institution. If you choose the former, please indicate clearly on your presentation slide or poster that your presentation has been approved. Whether or not approval is required for a small number of case reports should be in accordance with the judgment of each institution. Researches involving off-label use must be approved prior to start of research. If "Not Applicable" is checked for the study which includes the contents considered to require approval by the Ethics Committee or the institution, the abstract may be rejected.

Regarding acceptance and rejection

• The acceptance or rejection of the program will be determined after all review process.
• Acceptance notification will be sent to you by email in early March.
• The details about presentation will be announced on this website.